Cooper Companies 過去の業績

過去基準チェック /36

Cooper Companiesの収益は年間平均-14.7%の割合で減少していますが、 Medical Equipment業界の収益は年間増加しています。収益は年間1.9% 9.4%割合で増加しています。 Cooper Companiesの自己資本利益率は4.5%であり、純利益率は9.4%です。

主要情報

-14.7%

収益成長率

-14.8%

EPS成長率

Medical Equipment 業界の成長	-9.5%
収益成長率	9.4%
株主資本利益率	4.5%
ネット・マージン	9.4%
次回の業績アップデート	05 Dec 2024

Recent updates

収支内訳

Cooper Companies の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

LSE:0I3I 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
31 Jul 24	3,804	359	1,527	154
30 Apr 24	3,732	340	1,521	152
31 Jan 24	3,666	291	1,580	145
31 Oct 23	3,593	294	1,530	137
31 Jul 23	3,514	275	1,488	130
30 Apr 23	3,427	288	1,467	122
31 Jan 23	3,380	375	1,350	116
31 Oct 22	3,308	386	1,338	110
31 Jul 22	3,219	431	1,297	107
30 Apr 22	3,139	948	1,238	103
31 Jan 22	3,029	939	1,205	98
31 Oct 21	2,923	2,945	1,142	93
31 Jul 21	2,845	2,916	1,122	93
30 Apr 21	2,660	2,355	1,054	90
31 Jan 21	2,465	2,249	997	93
31 Oct 20	2,431	238	991	93
31 Jul 20	2,441	278	937	91
30 Apr 20	2,542	343	972	91
31 Jan 20	2,672	454	981	88
31 Oct 19	2,653	467	993	87
31 Jul 19	2,613	446	981	86
30 Apr 19	2,594	427	957	87
31 Jan 19	2,571	366	944	87
31 Oct 18	2,533	140	973	85
31 Jul 18	2,443	128	907	81
30 Apr 18	2,339	131	864	76
31 Jan 18	2,230	175	823	72
31 Oct 17	2,139	373	799	69
31 Jul 17	2,096	345	756	68
30 Apr 17	2,055	329	739	67
31 Jan 17	2,016	298	726	67
31 Oct 16	1,967	274	711	65
31 Jul 16	1,904	250	679	63
30 Apr 16	1,851	207	666	64
31 Jan 16	1,801	194	656	64
31 Oct 15	1,797	204	661	65
31 Jul 15	1,810	198	659	67
30 Apr 15	1,780	241	655	66
31 Jan 15	1,758	259	648	66
31 Oct 14	1,718	270	639	66
31 Jul 14	1,661	296	632	64
30 Apr 14	1,640	297	623	63
31 Jan 14	1,611	293	618	61

質の高い収益: 0I3Iは高品質の収益を持っています。

利益率の向上: 0I3Iの現在の純利益率 (9.4%)は、昨年(7.8%)よりも高くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: 0I3Iの収益は過去 5 年間で年間14.7%減少しました。

成長の加速: 0I3Iの過去 1 年間の収益成長率 ( 30.5% ) は、5 年間の平均 ( 年間-14.7%を上回っています。

収益対業界: 0I3Iの過去 1 年間の収益成長率 ( 30.5% ) Medical Equipment業界39.9%を上回りませんでした。

株主資本利益率

高いROE: 0I3Iの自己資本利益率 ( 4.5% ) は低いとみなされます。

Cooper Companies 過去の業績

過去 基準チェック /36

主要情報

最近の業績更新

The Cooper Companies, Inc. to Report Q4, 2024 Results on Dec 05, 2024

Third quarter 2024 earnings released: EPS: US$0.52 (vs US$0.43 in 3Q 2023)

The Cooper Companies, Inc. to Report Q3, 2024 Results on Aug 28, 2024

Second quarter 2024 earnings released: EPS: US$0.45 (vs US$0.20 in 2Q 2023)

The Cooper Companies, Inc. to Report Q2, 2024 Results on May 30, 2024

First quarter 2024 earnings released: EPS: US$0.41 (vs US$0.43 in 1Q 2023)

Recent updates

The Cooper Companies, Inc. to Report Q4, 2024 Results on Dec 05, 2024

Third quarter 2024 earnings released: EPS: US$0.52 (vs US$0.43 in 3Q 2023)

The Cooper Companies, Inc. Raises Earnings Guidance for the Fourth Quarter and Fiscal Year 2024

The Cooper Companies, Inc. to Report Q3, 2024 Results on Aug 28, 2024

Second quarter 2024 earnings released: EPS: US$0.45 (vs US$0.20 in 2Q 2023)

The Cooper Companies, Inc. Raises Earnings Guidance for the Fiscal Year 2024

The Cooper Companies, Inc. to Report Q2, 2024 Results on May 30, 2024

First quarter 2024 earnings released: EPS: US$0.41 (vs US$0.43 in 1Q 2023)

The Cooper Companies, Inc. Raises its Revenue Guidance for the Fiscal Year 2024

Girard Sharp LLP and Sauder Schelkopf LLC Files Lawsuit Against Coopersurgical, Inc. and the Cooper Companies, Inc

The Cooper Companies, Inc. Announces Resignation of Gary S. Petersmeyer from Board of Directors

Slater Vecchio LLP Files Class Action Lawsuit Against LifeGroup Global LLC, The Cooper Companies Inc, CooperSurgical Inc, and CooperSurgical Canada Inc

The Cooper Companies, Inc. to Report Q1, 2024 Results on Feb 29, 2024

The Cooper Companies, Inc., Annual General Meeting, Mar 19, 2024

The Cooper Companies, Inc. Announces Retirement of Gary S. Petersmeyer as Director

Full year 2023 earnings released: EPS: US$5.91 (vs US$7.83 in FY 2022)

The Cooper Companies, Inc. Provides Revenue Guidance for the Fiscal Year 2024

CooperCompanies Appoints Lawrence E. Kurzius to Board of Directors, Effective December 1, 2023

Now 20% undervalued after recent price drop

Now 22% undervalued after recent price drop

The Cooper Companies, Inc. to Report Q4, 2023 Results on Dec 07, 2023

The Cooper Companies, Inc. (NasdaqGS:COO) acquired Bakri Postpartum Balloon, Cervical Ripening Balloon, Doppler Blood Flow Monitor portfolio and gynecology surgery markets of Cook Medical Incorporated for $300 million.

Now 21% undervalued

The Cooper Companies, Inc. Updates Revenue Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$1.71 (vs US$2.00 in 3Q 2022)

Upcoming dividend of US$0.03 per share

The Cooper Companies, Inc. Provides Revenue Guidance for the Year 2023

Second quarter 2023 earnings released: EPS: US$0.80 (vs US$2.57 in 2Q 2022)

Senior VP & Chief Accounting Officer recently sold US$370k worth of stock

President of CooperVision recently sold US$414k worth of stock

First quarter 2023 earnings released: EPS: US$1.70 (vs US$1.93 in 1Q 2022)

The Cooper Companies, Inc. to Report Q1, 2023 Results on Mar 02, 2023

Upcoming dividend of US$0.03 per share

The Cooper Companies, Inc., Annual General Meeting, Mar 15, 2023

CooperCompanies Declares Cash Dividend, Payable on February 10, 2023

Full year 2022 earnings released: EPS: US$7.76 (vs US$59.85 in FY 2021)

The Cooper Companies, Inc. Initiates Earnings Guidance for the Fiscal Year 2023

Investor sentiment improved over the past week

The Cooper Companies, Inc. to Report Q4, 2022 Results on Dec 08, 2022

the Cooper Companies, Inc. Appoints Cynthia Lucchese to Board of Directors

the Cooper Companies, Inc. Updates Revenue Guidance for Fourth Quarter and Full year 2022

Third quarter 2022 earnings released: EPS: US$1.98 (vs US$12.49 in 3Q 2021)

the Cooper Companies, Inc. Updates Revenue Guidance for Fourth Quarter and Full Year Year 2022

CooperCompanies Appoints Nicholas Khadder as Its General Counsel and Corporate Secretary

The Cooper Companies, Inc. to Report Q3, 2022 Results on Aug 31, 2022

Upcoming dividend of US$0.03 per share

CooperCompanies Declares Semi-Annual Cash Dividend, Payable on August 11, 2022

The Cooper Companies, Inc. Provides Consolidated Earnings Guidance for the Third Quarter, Fourth Quarter and Full Year of Fiscal 2022

Second quarter 2022 earnings released: EPS: US$2.55 (vs US$2.39 in 2Q 2021)

Independent Director recently sold US$123k worth of stock

The Cooper Companies, Inc. Provides Revenue Earnings Guidance for the Fiscal Year 2022

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

The Cooper Companies, Inc. (NYSE:COO) signed a binding letter of intent to acquire Reproductive Health Business of Cook Medical for $880 million.

The Cooper Companies, Inc. to Report Q1, 2022 Results on Mar 03, 2022

Insufficient new directors

Inaugural dividend of US$0.03 per share

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

The Cooper Companies, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Independent Director recently sold US$201k worth of stock

The Cooper Companies, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of Fiscal 2021

Third quarter 2021 earnings released: EPS US$12.37 (vs US$1.12 in 3Q 2020)

CooperCompanies Announces MiSight® Approval from Chinese National Medical Products Administration

Inaugural dividend of US$0.03 per share

Independent Director recently sold US$165k worth of stock

The Cooper Companies, Inc.(NYSE:COO) dropped from Russell 1000 Growth-Defensive Index

Second quarter 2021 earnings released: EPS US$2.36 (vs US$0.23 in 2Q 2020)

the Cooper Companies, Inc. Provides Earnings Guidance for the Fiscal Year 2021

First quarter 2021 earnings released: EPS US$42.28 (vs US$1.84 in 1Q 2020)

Revenue beats expectations

過去基準チェック /36